(Q34002840)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20672005%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

review article

1 reference

title

Iron chelation therapy in myelodysplastic syndromes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20672005%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20672005%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Emanuela Messa

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20672005%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Daniela Cilloni

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20672005%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

20 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20672005%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

published in

Advances in Hematology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20672005%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20672005%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

756289

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20672005%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 3.0 Unported

9 February 2020

copyright license

start time

1 January 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Long-term efficacy and safety of deferasirox.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

The role of iron in patients after bone marrow transplantation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

The iron chelator deferasirox protects mice from mucormycosis through iron starvation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Early clinical impact of iron overload in stem cell transplantation. A prospective study.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Natural resistance, iron and infection: a challenge for clinical medicine

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

LPI-labile plasma iron in iron overload

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

The role of labile iron pool in cardiovascular diseases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Pathogenesis, etiology and epidemiology of myelodysplastic syndromes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

International scoring system for evaluating prognosis in myelodysplastic syndromes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Results of long-term iron-chelating therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

The 5q- syndrome: a single-institution study of 43 consecutive patients.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Myelodysplastic syndromes--coping with ineffective hematopoiesis

5 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F756289

Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F756289

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F756289

Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F756289

Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F756289

Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F756289

Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F756289

Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F756289

A magnetic resonance imaging study of iron overload in hemopoietic stem cell transplant recipients with increased ferritin levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F756289

Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F756289

Myelodysplasia paranoia: iron as the new radon

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F756289

Iron chelation therapy in myelodysplastic syndrome - Cui bono?

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F756289

Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905902

29 October 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F756289

Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome

21 January 2018

1 reference

12 December 2020

Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts

1 reference

12 December 2020

Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes

1 reference

12 December 2020

Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron

1 reference

12 December 2020

Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis

1 reference

12 December 2020

Predicting survival and leukemic evolution in patients with myelodysplastic syndrome

1 reference

12 December 2020

The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload

1 reference

12 December 2020

Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation

1 reference

12 December 2020

Iron overload in myelodysplastic syndromes: a Canadian consensus guideline

1 reference

12 December 2020

Clinical consequences of acquired transfusional iron overload in adults

1 reference

12 December 2020

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes

1 reference

12 December 2020

Survival and causes of death in thalassaemia major

1 reference

12 December 2020

Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?

1 reference

12 December 2020

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload

1 reference

12 December 2020

No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique

1 reference

12 December 2020

Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation

1 reference

12 December 2020

Consensus statement on iron overload in myelodysplastic syndromes

1 reference

12 December 2020

Identifiers

DOI

10.1155/2010/756289

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20672005%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20672005%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference